welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”
rareRelated
-
Researchers Overcome Hurdle in CRISPR Gene Editing for Muscular DystrophyThe gene editing technique known as CRIS...
-
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
-
Gene Therapy for Duchenne Muscular DystrophyGene Therapy for Duchenne Muscular Dyst...
-
UCLA’s Duchenne Muscular Dystrophy Research Funded by a Stem Cell AgencyScientists at the UCLA Eli and Edythe Br...
-
Microdystrophin Gene Transfer Study in Adolescents and Children With DMDThis is a randomized, controlled, open-l...
-
Clinical trial of gene therapy for Duchenne muscular dystrophy underway at University of Florida HealthScreening has resumed in a clinical tria...
-
New CRISPR Method Takes on Duchenne Muscular DystrophyThe advance of CRISPR gene editing techn...
